Mineralys Therapeutics (MLYS) Retained Earnings (2022 - 2026)

Mineralys Therapeutics has disclosed Retained Earnings across 5 years of filings, most recently posting -$496.5 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$496.5 million, down 44.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$496.5 million (down 44.04% YoY), and the FY2025 annual result was -$457.2 million, down 51.12% from the prior year.
• Retained Earnings came in at -$496.5 million for Q1 2026 at Mineralys Therapeutics, down from -$457.2 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$52.8 million in Q4 2022 to a low of -$496.5 million in Q1 2026.
• The 5-year median for Retained Earnings is -$225.4 million (2024), against an average of -$245.8 million.
• Across the five-year window, Retained Earnings plunged 154.12% in 2024 and plunged 44.04% in 2026, its largest moves.
• Mineralys Therapeutics' Retained Earnings stood at -$52.8 million in 2022, then plunged by 136.14% to -$124.7 million in 2023, then slumped by 142.58% to -$302.5 million in 2024, then tumbled by 51.12% to -$457.2 million in 2025, then declined by 8.6% to -$496.5 million in 2026.
• The last three Retained Earnings figures came in at -$496.5 million (Q1 2026), -$457.2 million (Q4 2025), and -$424.9 million (Q3 2025), per Business Quant data.